HC Wainwright & Co. Reiterates Buy on Belite Bio, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on Belite Bio (NASDAQ:BLTE) and lowered the price target from $58 to $55.
June 05, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on Belite Bio and lowered the price target from $58 to $55.
The news of HC Wainwright & Co. analyst reiterating a Buy rating on Belite Bio and lowering the price target from $58 to $55 may not have a significant short-term impact on the stock price. However, it indicates that the analyst still has a positive outlook on the company, which could be beneficial for investors in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100